Case report details severe pneumonitis in a lung adenocarcinoma patient post-allogeneic HSCT, indicating critical safety concerns.
Immune checkpoint inhibitors (ICIs) are essential treatments for lung cancer, but their safety following allogeneic haematopoietic stem cell transplantation (allo‐HSCT) remains unclear. We report a case of a 66‐year‐old man who underwent umbilical cord blood transplantation for acute lymphoblastic leukaemia and later developed lung adenocarcinoma. Pembrolizumab monotherapy was initiated, but the patient developed severe steroid‐refractory immune‐related pneumonitis, leading to mortality 56 days after treatment initiation. Given the scarcity of reports on ICI use in lung cancer patients with prior HSCT, this case highlights critical safety considerations.
No takes yet. Share an insight, caveat, or question.
Yamamoto et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: